Therapeutic Solutions International Reports its
NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA
Cleared Cancer Immunotherapy in Animal Model of
Cancer
New
Data Supports Development of Patented Formulation of Blueberry
Extract Pterostilbene as an Adjuvant to Immuno-Oncology
Treatments
OCEANSIDE, CA -- July
22, 2019 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) reported today
positive animal data demonstrating synergy between its commercially
available NanoStilbene™ nutraceutical product [1] together with
anti-CTLA4 antibody, which is the mouse equivalent of Ipilimumab
(Yervoy®),
an FDA cleared immunotherapeutic which belongs to the family of
drugs called "checkpoint inhibitors". The new data
supports the possibility that
NanoStilbene™, a proprietary formulation of pterostilbene
[2], may
increase effectiveness of drugs that activate the immune system to
kill cancer.
"The current set of
animal experiments demonstrate not only that NanoStilbene™
enhances the
ability
of the CTLA-4 antibody to reduce tumor size, but also that
NanoStilbene™ augments the number of lymphocytes entering the
tumor. This
data,
together with previous publications that pterostilbene itself
suppresses a wide variety of tumors, support the possible
development of our nutraceutical as an adjuvant to numerous
immunotherapies" said Thomas Ichim,
Ph.D., Board Member of
TSOI and coinventor on the Company's patents.
Numerous independent
laboratories have published in the peer reviewed literature that
pterostilbene decreases the growth of prostate cancer [3], breast
cancer [4], glioma [5], liver cancer [6], esophageal cancer [7],
and melanoma [8]. The advantage of NanoStilbene™ as compared
to pterostilbene capsules, which are widely available, is that the
proprietary nanoformulation allows substantially higher
concentrations of
pterostilbene
to reach the cancer cells.
"We at Therapeutic
Solutions International are focused on a Science First approach to
development of all of our products. The new data disclosed
today further supports our existing body of knowledge and patent
filings which expand on our issued patent # 9,682,047, which covers
utilization of pterostilbene with other immunotherapies"
said Timothy Dixon,
President and CEO of the Company. "We plan to expand our current
studies in several areas, including exploring the
effects
of NanoStilbene™ on adoptive cellular immunotherapy and CAR-T
cells."
[1] http://www.youcanordernow.com/NanoStilbene™-PKE-60ml-wgraduated-1ml-glass-eyedropper_p_23.html
[2] https://mynanostilbene.com/?page_id=159
[3] Dhar
et al. Oncotarget. 2015 Sep
29;6(29):27214-26.
[4] Wakimoto et al. Differential
Anticancer Activity of Pterostilbene Against Three Subtypes of
Human Breast Cancer Cells. Anticancer Res. 2017
Nov;37(11):6153-6159.
[5] Huynh et al. Pterostilbene suppressed irradiation-resistant
glioma stem cells by modulating GRP78/miR-205 axis. J Nutr
Biochem.
2015 May;26(5):466-75.
[6] Qian et al. Pterostilbene inhibits MTA1/HDAC1 complex leading
to PTEN acetylation in hepatocellular carcinoma. Biomed
Pharmacother. 2018 May;101:852-859.
[7] Feng et al. Pterostilbene Inhibits the Growth of Human
Esophageal Cancer Cells by Regulating Endoplasmic Reticulum Stress.
Cell Physiol Biochem.
2016;38(3):1226-44.
[8] Benlloch et al. Pterostilbene
Decreases the Antioxidant Defenses of Aggressive Cancer Cells In
Vivo: A Physiological Glucocorticoids- and Nrf2-Dependent
Mechanism. Antioxid
Redox
Signal. 2016 Jun 10;24(17):974-90.
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
Safe Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION